Navigation Links
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
Date:4/20/2012

NEW YORK, April 20, 2012 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Chelsea Therapeutics International, Ltd. ("Chelsea" or the "Company") (Nasdaq: CHTP).   

(Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO )

The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose that:  (1) Chelsea's Northera (droxidopa) product, an orally-active synthetic precursor of norepinephrine being developed for the treatment of symptomatic neurogenic orthostatic hypotension, would not receive approval from the U.S. Food and Drug Administration; and (2) the Company's numerous statements regarding the safety and efficacy of the product, as well as reportedly positive results from Northera's clinical trials, were materially false and misleading.

Request more information now by clicking here:  www.faruqilaw.com/CHTP

Take Action
If you purchased Chelsea securities between November 3, 2008 and March 28, 2012 and would like to discuss your legal rights, visit www.faruqilaw.com/CHTP.  You can also contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com or fmcconville@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding Chelsea's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case.  All communications will be treated in a confidential matter.

FARUQI & FARUQI, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn:  Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Francis McConville, Esq.
fmcconville@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330

 


'/>"/>
SOURCE Faruqi & Faruqi, LLP
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Faruqi & Faruqi, LLP Announces Investigation of ZELTIQ Aesthetics, Inc.
2. Faruqi & Faruqi, LLP Announces Investigation of BioSante Pharmaceuticals, Inc.
3. Faruqi & Faruqi, LLP Announces Investigation of GenVec, Inc.
4. Supreme Court to Decide Overtime Fate for Pharmaceutical "Sales Representatives" -- JacksonWhite, Kingsley & Kingsley and Sanford Wittels & Heisler
5. Frost & Sullivan: Industry Push toward Quantitative Imaging Positions Computer Aided Detection and Diagnosis Adequately for Renewed Clinical Expansion
6. Frost & Sullivan: U.S. Nuclear Medicine and PET Imaging Systems Market Witnessed a Rebound in 2010, With PET Blazing the Trail
7. Frost & Sullivan Recognizes Sensear for Innovative and Effective Product Differentiation in the PPE Market
8. Talysts CEO is Nominated for the Ernst & Young Entrepreneur of the Year Award
9. R&D Trends: Depression - Clinical attrition driven by mature market conditions
10. Fi Asia-China, Hi & Ni China is Ready for Return on June 2012 in Shanghai
11. PediaVision to Conduct Free Screenings With "Spot" at Kips Bay Boys & Girls Club
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... MELBOURNE, Australia , Feb. 21, 2017  IBM (NYSE: ... IBM Watson,s ability to detect abnormalities of the eye,s retina. ... trained a research version of Watson to recognize abnormalities in ... insights and speed in their early identification of patients who ... glaucoma, a leading cause of blindness in the developed world. ...
(Date:2/21/2017)... Medical Oxygen Concentrators Market: Overview ... Medical oxygen concentrators are used by patients ... having low level of oxygen in their blood ... are to be used only with prescription and ... concentrators work either on rechargeable lithium batteries or ...
(Date:2/21/2017)...   BeyondSpring Pharmaceuticals , a clinical stage ... immuno-oncology cancer therapies, today announced that the Company,s ... 2 trial of BeyondSpring,s innovative lead asset, ... lung cancer (NSCLC) with Docetaxel has been selected ... Immuno-Oncology Symposium in Orlando, Fla. ...
Breaking Medicine Technology:
(Date:2/21/2017)... ... February 21, 2017 , ... Individuals who have been diagnosed ... surgery, treatment, therapy and management. Regular exercise in proper environments has been shown ... their diseases. On February 23, 2017, 1:00-2:00 p.m. E.S.T., a dynamic HydroWorx ...
(Date:2/21/2017)... NJ (PRWEB) , ... February 21, 2017 , ... ... research and conference coverage in veterinary medicine, will be launching its first bi-monthly ... animal health and medicine, business and practice management, and One Health. , ...
(Date:2/21/2017)... ... 2017 , ... Atlanta-based Jvion, the leading cognitive clinical science ... practice. Predixion, which raised $42M+ to date, received $20M in its third ... Ventures, and Software AG , will bring top industry talent and an impressive ...
(Date:2/21/2017)... ... February 21, 2017 , ... A February 6 article on Healio ... It found that the treatments have led to significant improvements in weight loss and ... efforts. It also noted very few problematic results relating to the treatment. Beverly Hills ...
(Date:2/20/2017)... Ill. (PRWEB) , ... February 20, 2017 , ... ... to reduce the rate at which women are called back for additional examinations ... journal Radiology . , In 2011, the U.S. Food and Drug Administration ...
Breaking Medicine News(10 mins):